Liquidia Corporation
NASDAQ:LQDABiotechnology
+$0.23 today
- Market cap
- $5.08B
- Beta
- 0.59
- P/E (TTM)
- 271.8
- EPS (TTM)
- $0.25
Volume 1.22M
Average 1.50M
LQDA Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Liquidia CorporationNASDAQ: LQDA
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables turns negative
Q2 FY2026 accounts payables was -$1.15M, compared with $1.95M a year earlier. Trailing-twelve-month accounts payables was -$11.7M.
Context
- Accounts payables amounted to 1.6% of revenue in FY2025, down 15.0 pp from a year earlier.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near -$1.15M or moves back toward the trailing-twelve-month quarterly average of -$2.93M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (2.59M) USD
- Year-over-year change
- -211.3%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.59M) | -211.3% |
| FY2024 | 2024-12-31 | 2.33M | +302.3% |
| FY2023 | 2023-12-31 | (1.15M) | -241.5% |
| FY2022 | 2022-12-31 | 814K | +110.8% |
| FY2021 | 2021-12-31 | (7.56M) | — |
Accounts Payables vs competitors
How LQDA compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -361.8% is the lowest of 2, against a peer median of +2736.6%.
- Accounts payables amounts to 2.6% of revenue for LQDA, versus a peer median of 2.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $170.85M USD | +2736.6% | +26.0% | 15.0% | |
| LTM Jun 2026 | $81.2M USD | — | — | 2.6% | |
| LTM Jun 2026 | $11.7M USD | -361.8% | — | 2.6% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 0 SEK | — | — | 0.0% |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding LQDA) | — | +2736.6% | +26.0% | 2.6% | |
Competitors are the stored peer set for LQDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (34.58M) | (41.02M) | (78.5M) | (130.39M) | (68.92M) |
| Depreciation & Amortization | 5.61M | 3.65M | 2.18M | 2.2M | 1.53M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.75M | 9.3M | 10.09M | 18.81M | 29.47M |
| Change in Working Capital | (12.38M) | (2.16M) | 5.87M | (4.79M) | (24.18M) |
| Accounts Receivables | (2.99M) | (2.03M) | 956K | 1.34M | (51.37M) |
| Inventory | 0 | 0 | 0 | (241K) | (22.99M) |
| Accounts Payables | (7.56M) | 814K | (1.15M) | 2.33M | (2.59M) |
| Other Working Capital | (1.83M) | (945K) | 6.07M | (8.22M) | 52.77M |
| Other Non-Cash Items | 566K | 1.64M | 18.8M | 20.76M | 26.42M |
| Operating Cash Flow | (34.04M) | (28.59M) | (41.56M) | (93.42M) | (35.69M) |
| Capital Expenditures | (107K) | (592K) | (1.29M) | (4.95M) | (4.34M) |
| Acquisitions (Net) | 0 | 5K | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (10M) | (3.49M) | (2M) |
| Investing Cash Flow | (107K) | (587K) | (11.29M) | (8.44M) | (6.34M) |
| Debt Repayment | (420K) | 8.96M | 19.37M | 52.5M | 53.82M |
| Common Stock Issued | 21.71M | 54.46M | 24.24M | 138.55M | 4.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.03M | 1.55M | (363K) | 3.61M | 1.08M |
| Financing Cash Flow | 26.32M | 64.96M | 43.25M | 194.66M | 59.73M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (3.5M) |
| Net Change in Cash | (7.82M) | 35.79M | (9.6M) | 92.8M | 14.2M |
| Free Cash Flow | (34.14M) | (29.18M) | (42.85M) | (98.37M) | (40.02M) |
Liquidia Corporation
NASDAQ:LQDA
Intrinsic Alpha fair value
Locked
Current Price
$56.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.